One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest deep-dive, and the picks on the public ledger. No firehose, no FOMO.

We Use Cookies

We use cookies to enhance your experience, analyze site traffic, and for marketing purposes. By clicking "Accept," you agree to our use of cookies. Read our Privacy Policy.

TRVI

BULL

2026-06-19

Overnight Institutional Flow Signal · Healthcare

See the 2026-06-19 Morning Briefing

Score

7/10

Move

6.6%

Flow

$2.0M

Engine Flags(1/5 patterns matched — diagnostic, not a trade signal)

📈

Strong Call FlowAggressive bullish accumulation

AI Trade Thesis

TRVI BULL $18C Jul 17 '26. The institutional call sweep aligns with the dominant daily scan direction and captures a powerful technical breakout following a successful, non-dilutive lock-up expiration. Backed by a $334 million cash runway through 2030 and upcoming Phase 3 trials for Haduvio, the stock has strong fundamental support. Entry is favorable near the current spot of $17.21 with a target of $21.00. Risk is limited to a broader market growth-selloff or trial design delays.

Flow Breakdown

Call Volume

$2.0M

Put Volume

$24K

Flow Intent

DIRECTIONAL

Catalyst

Technical Breakout

More Bullish Flow · 2026-06-19

LQDA8/10 VRTX7/10 RVMD6/10 QS9/10 FRO9/10 TWLO8/10

Recommended Setup

ContractO:TRVI260717C00018000

Strike$18.00

Expiration2026-07-17

Mid Price$1.07

Contract Score10.188/10

Risk/Reward0.1:1

Delta0.46

Key Levels

Resistance$17.61

Support$13.20

Price$17.21

SMA 50 / 200$14 / $12

52W Range$5 — $18

RSI (14)75

News & Catalyst Analysis

Key Headline

Trevi Therapeutics surged to an all-time high as major lock-up expiration on 128 million shares passes without selling pressure

News Summary

Trevi Therapeutics is experiencing strong upward momentum, hitting multi-year highs as investors digest major positive developments, including the expiration of a 128-million-share lock-up on June 16 with zero selling pressure. The market is increasingly optimistic about lead candidate Haduvio (oral nalbuphine ER) for chronic cough in IPF, supported by a massive $334M cash runway extending through 2030 and upcoming pivotal trial initiations. Institutional call buying is expanding alongside this breakout, indicating that smart money is actively positioning for further upside rather than hedging.

Flow Intent Analysis

The options flow is highly directional as the $2M volume represents new, aggressive upside exposure initiated during a clear technical breakout rather than protective hedging against a decline.

One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest deep-dive, and the picks on the public ledger. No firehose, no FOMO.

How We Read This Flow

Plain-English explainers on the methodology behind signals like this one.

View all →

One email a week. Catch up in five minutes.

TRVI

Key Headline

News Summary

Flow Intent Analysis

One email a week. Catch up in five minutes.

How We Read This Flow

Why 90% of Options Traders Fail: Building Better Retail Options Trading Systems

A $19/mo Options Signal Service Review: Why Skipping Bad Days is Your Greatest Edge

What Gets Pushed to My Phone at 7:30 AM ET (Weekly Engine Recap)